All PlansCoverageMedium impact
Molecular Markers in Fine Needle Aspirates of the Thyroid
Blue Cross & Blue Shield of Mississippi·MS · Endocrinology, General Surgery, ENT (Ear, Nose & Throat) +1 more·Medical Policy
We identified it
Jun 20, 2026
Summary
This is a new medical policy establishing coverage guidelines for molecular marker testing in thyroid fine needle aspirates. The policy defines when tests like ThyroSeq v3, Afirma Gene Expression Classifier, and other genetic panels are appropriate for patients with indeterminate thyroid nodule cytology results.
Action Required
Review current thyroid molecular testing orders to ensure they align with new coverage criteria. Verify that orders for ThyroSeq v3, Afirma GSC, ThyGenX, and ThyraMIR tests are only submitted for patients with indeterminate FNA cytology (atypia of uncertain significance, follicular lesion of undetermined significance, or suspicious for malignancy). Update provider education materials to reflect appropriate test ordering criteria.